Neoleukin Therapeutics (NASDAQ:NLTX) Trading Up 3.8% – Still a Buy?

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) shares traded up 3.8% during trading on Tuesday . The stock traded as high as $18.95 and last traded at $18.33. 129,967 shares changed hands during trading, an increase of 159% from the average session volume of 50,104 shares. The stock had previously closed at $17.66.

Neoleukin Therapeutics Stock Performance

The business has a 50-day simple moving average of $19.47 and a 200-day simple moving average of $21.89. The company has a market cap of $172.27 million, a price-to-earnings ratio of -5.89 and a beta of 1.11.

Neoleukin Therapeutics Company Profile

Neoleukin Therapeutics, Inc is a clinical‐stage biotechnology company focused on the design and development of de novo protein therapeutics for the treatment of cancer and immune‐mediated diseases. Leveraging computational protein engineering, the company creates novel cytokine mimetics intended to provide targeted immune activation while minimizing the toxicities associated with natural cytokines. This platform is anchored by proprietary algorithms and structure‐based design tools that enable the rapid generation of therapeutic candidates with optimized stability, affinity and specificity.

The company’s lead candidate, NL-201, is a next‐generation cytokine therapy designed to engage interleukin‐2 and interleukin‐15 receptors on immune effector cells, with the goal of enhancing anti‐tumor responses.